Retirement Systems of Alabama Cuts Stake in Repligen Co. (NASDAQ:RGEN)

Retirement Systems of Alabama lessened its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 1.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 63,272 shares of the biotechnology company’s stock after selling 865 shares during the period. Retirement Systems of Alabama owned approximately 0.11% of Repligen worth $9,416,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the business. Andra AP fonden acquired a new position in shares of Repligen in the 2nd quarter valued at $25,000. International Assets Investment Management LLC acquired a new position in shares of Repligen in the second quarter valued at about $33,000. UMB Bank n.a. raised its stake in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the last quarter. Blue Trust Inc. lifted its holdings in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares during the period. Finally, Resources Management Corp CT ADV purchased a new stake in Repligen in the third quarter valued at approximately $37,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on RGEN shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Finally, Wells Fargo & Company started coverage on Repligen in a report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Trading Up 2.9 %

Shares of RGEN stock opened at $160.92 on Tuesday. The stock has a 50 day simple moving average of $142.66 and a 200-day simple moving average of $141.59. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The company has a market cap of $9.02 billion, a price-to-earnings ratio of -434.92, a PEG ratio of 4.64 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the business posted $0.23 earnings per share. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, equities research analysts expect that Repligen Co. will post 1.54 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.